R
Regina Garcia-Delgado
Publications - 7
Citations - 104
Regina Garcia-Delgado is an academic researcher. The author has contributed to research in topics: Internal medicine & Ruxolitinib. The author has an hindex of 3, co-authored 4 publications receiving 70 citations.
Papers
More filters
Journal ArticleDOI
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial
Moshe Mittelman,Uwe Platzbecker,Boris V. Afanasyev,Sebastian Grosicki,Raymond S.M. Wong,Achilles Anagnostopoulos,Benjamin Brenner,C. Denzlinger,Giuseppe Rossi,Arnon Nagler,Regina Garcia-Delgado,Maria Socorro O Portella,Zewen Zhu,Dominik Selleslag +13 more
TL;DR: The most common grade 3 and grade 4 adverse events were fatigue and fatigue, and clinically meaningful efficacy was defined as 30% absolute difference between groups.
Journal ArticleDOI
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Srdan Verstovsek,Haifa Kathrin Al-Ali,John Mascarenhas,Andrew C. Perkins,Alessandro M. Vannucchi,Sanjay R. Mohan,Bart L. Scott,Dariusz Woszczyk,Steffen Koschmieder,Regina Garcia-Delgado,Rejtő László,Jesse McGreivy,Wayne Rothbaum,Jean-Jacques Kiladjian +13 more
TL;DR: Navtemadlin (KRT-232) as mentioned in this paper restores p53 activity to drive apoptosis of wild-type TP53 tumor cells by inducing expression of pro-apoptotic Bcl-2 family proteins.
Journal ArticleDOI
An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor
Regina Garcia-Delgado,Donal P. McLornan,László Rejtő,Eric Jourdan,Haifa Kathrin Al-Ali,Andrzej Pluta,Marek Hus,Joanne Ewing,Irum Khan,Holger Hebart,Philipp J. Jost,Sebastian Grosicki,Wayne Rothbaum,Jesse McGreivy,Srdan Verstovsek +14 more
TL;DR: KRT-232 is a potent and selective, oral, small molecule drug that targets MDM2 and preventsMDM2-mediated p53 inhibition, allowing p53 to mediate tumor cell-cycle arrest and apoptosis in response to cellular stress or DNA damage.
Journal ArticleDOI
A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera
Jason Gotlib,Nashat Y. Gabrail,Casey O'Connell,Regina Garcia-Delgado,Timothy Sbardellati,Wayne Rothbaum,Jesse McGreivy,Claire N. Harrison,Jean-Jacques Kiladjian +8 more
TL;DR: This randomized, open-label study aims to evaluate the efficacy, safety, and pharmacokinetics of KRT-232 compared with ruxolitinib in up to 320 patients with phlebotomy-dependent PV.
Journal ArticleDOI
An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib
John Mascarenhas,Alessandro M. Vannucchi,Adam J. Mead,Regina Garcia-Delgado,Andrzej Pluta,Hope Qamoos,Anne Uyei,Damaj Gandhi Laurent,Haifa Kathrin Al-Ali +8 more
TL;DR: It is hypothesized that KRT-232 may deliver synergistic efficacy and disease modification when combined with ruxolitinib by targeting a complementary mechanism that promotes apoptosis in malignant MF clones and has the potential to lower the apoptotic threshold of malignant cells that are deprived of growth factor and cytokine support.